Ravulizumab — Dosing in CKD & Dialysis
Ravulizumab (Complement C5 Inhibitor (monoclonal antibody)): renal dosing adjustments, dialyzability (Not expected to be removed: pharmacokinetics not clinically different in patients receiving dialysis (Ultomiris label 12.3); about 148 kDa (11). Plasma exchange, plasmapheresis and IVIg lower levels
Reviewed by Matt · November 16, 2026